P1vital gains acceptance of the first PReDicT Study publication!

P1vital are pleased to announce that we have gained acceptance of our first PReDicT study publication: “The Clinical Effectiveness of Using a Predictive Algorithm to Guide Antidepressant Treatment in Primary Care (PReDicT): an open-label, randomised controlled trial”.

Journal: Neuropsychopharmacology

DOI: 10.1038/s41386-021-00981-z

The objective of the PReDicT Project (Predicting Response to Depression Treatment) was to conduct clinical, health economic and commercial research to validate the clinical performance and to complete the pre-commercial development of the P1vital® PReDicT Test, a novel medical device to improve the treatment and management of depression in clinical practice. The project was co-funded by the Horizon 2020 programme of the European Union.

To view the article, please click here